KALA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
KALA BIO, INC. (KALA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.80% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-04-15
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 4.10%, a 3.02% increase year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.98%.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2022-03-31 was 1.43%, a 186.00% increase year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2021-03-31 was 0.50%, a 65.75% decline year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.80%, a 9.83% increase from fiscal 2024.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.46%, a 2.54% decline from fiscal 2023.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.55%, a 148.25% increase from fiscal 2022.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.43%, a 186.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 3.80% 10-K · filed 2026-04-15 | |||
| 2025-09-30 | 3.80% 10-Q · filed 2025-11-19 | |||
| 2025-06-30 | 4.07% 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | 4.10% 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | 3.46% 10-K · filed 2026-04-15 | |||
| 2024-09-30 | 3.46% 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 3.98% 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | 3.98% 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | 3.55% 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 3.55% 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 3.55% 10-Q · filed 2023-08-04 | |||
| 2022-12-31 | 1.43% 10-K · filed 2024-03-29 | |||
| 2022-09-30 | 1.43% 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 1.43% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.43% 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 0.50% 10-K · filed 2023-03-03 | |||
| 2021-09-30 | 0.50% 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 0.50% 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 0.50% 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | 0.37% 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 0.37% 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 0.42% 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 1.46% 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | 1.44% 10-K · filed 2021-02-25 | |||
| 2019-09-30 | 1.44% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 1.87% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 2.49% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 2.63% 10-K · filed 2020-02-12 | |||
| 2018-09-30 | 2.63% 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 2.63% 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | 2.63% 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | 1.81% 10-K · filed 2019-03-12 | |||
| 2017-09-30 | 1.81% 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | 1.81% 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |